Febrile neutropenia is an emergent complication of chemotherapy and has been historically managed in the hospital. It has been established that a subset of cancer patients with febrile neutropenia are stable enough to be managed as outpatients. Unfortunately, geriatric cancer patients are perceived as high risk based on their chronologic age and continue to be admitted. The MASCC risk index and CISNE are validated tools that assist clinicians in identifying stable febrile neutropenic patients who may not require admission for management. The effectiveness of these tools has not been evaluated specifically in geriatric cancer patients being treated in the community setting.